Ftse Mib
36.267,63
0,00%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
102.642,03
1,62%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Actinium Pharmaceuticals Inc (ATNM) Actinium Pharmaceuticals Inc (ATNM) Notizie

Actinium Pharmaceuticals Inc

ATNM
1,34
0,125 (10,29%)
18 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
27/11/202422:30EDGAR2Form 8-K - Current report
18/11/202414:00PRNUSActinium Pharmaceuticals Highlights Antibody Radiation..
14/11/202422:57EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202400:51EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
06/11/202413:30EDGAR2Form ARS - Annual Report to Security Holders
05/11/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/11/202423:05EDGAR2Form 8-K - Current report
05/11/202423:00EDGAR2Form DEF 14A - Other definitive proxy statements
04/11/202413:30PRNUSActinium Pharmaceuticals Appoints Accomplished Biopharma..
20/9/202414:00PRNUSActinium Pharmaceuticals Announces Publication of Results..
05/8/202423:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/8/202413:30EDGAR2Form 8-K - Current report
05/8/202413:00PRNUSActinium Provides Regulatory Update on Planned BLA Filing..
01/8/202414:00PRNUSActinium Expands Patent Coverage Over Iomab-ACT, its..
25/7/202414:45PRNUSActinium Announces FDA Clearance of Iomab-ACT Targeted..
25/7/202413:30PRNUSActinium Pharmaceuticals to Present at the 3rd Annual..
17/6/202414:00PRNUSActinium Presents First Ever Data Demonstrating Actimab-A in..
14/6/202414:30PRNUSActinium Highlights Oral Presentation at EHA 2024 Annual..
11/6/202414:30PRNUSActinium Announces Results of Actimab-A + CLAG-M Combination..
10/6/202414:30PRNUSActinium Highlights Mutation Data from the Phase 3 SIERRA..
15/5/202414:30PRNUSActinium to Host KOL Webinar to Discuss Iomab-ACT Commercial..
15/5/202400:38PRNUSActinium Announces Oral Presentation Detailing Improved..
13/5/202414:30PRNUSActinium Announces Multiple Abstracts Highlighting its..
07/5/202414:00PRNUSActinium Announces KOL Webinar to Highlight Recently..
18/4/202414:00PRNUSActinium Highlights Ability of Iomab-B to Overcome High-Risk..
01/4/202414:00PRNUSActinium Announces Iomab-B Phase 3 SIERRA Trial Results..
26/3/202412:18PRNUSActinium Announces Clinical Trial to Study Iomab-ACT..
11/3/202412:30PRNUSActinium Pharmaceuticals Launches Actinium-225 Focused..
26/2/202413:30PRNUSActinium Announces Iomab-B Markedly Increases Long Term..
23/2/202413:30PRNUSActinium Highlights Improved Survival with Iomab-B in TP53..
09/2/202422:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202423:03EDGAR2Form S-3/A - Registration statement under Securities Act of..
Apertura: 1,22 Min: 1,22 Max: 1,40
Chiusura: 1,215

La tua Cronologia

AMEX
ATNM
Actinium Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network